Evidence map›Paper›PMID 25512429›Full record

ArticleAntimicrobial agents and chemotherapy2015

Small-molecule xenomycins inhibit all stages of the Plasmodium life cycle.

Jessey Erath, Julio Gallego-Delgado, Wenyue Xu, Grasiella Andriani, Scott Tanghe, Katerina V Gurova, Andrei Gudkov, Andrei Purmal, Elena Rydkina, Ana Rodriguez

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Inhibitory Compounds Targeting Plasmodium falciparum Gyrase B.Antimicrobial agents and chemotherapy · 2021
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jessey ErathNew York University School of Medicine, Department of Microbiology, Division of Parasitology, New York, New York, USA.
Julio Gallego-DelgadoNew York University School of Medicine, Department of Microbiology, Division of Parasitology, New York, New York, USA.
Wenyue XuNew York University School of Medicine, Department of Microbiology, Division of Parasitology, New York, New York, USA.
Grasiella AndrianiNew York University School of Medicine, Department of Microbiology, Division of Parasitology, New York, New York, USA.
Scott TangheNew York University School of Medicine, Department of Microbiology, Division of Parasitology, New York, New York, USA.
Katerina V GurovaRoswell Park Cancer Institute, Department of Cell Stress Biology, Buffalo, New York, USA.
Andrei GudkovRoswell Park Cancer Institute, Department of Cell Stress Biology, Buffalo, New York, USA.
Andrei PurmalIncuron LLC, Buffalo, New York, USA.
Elena RydkinaRoswell Park Cancer Institute, Department of Cell Stress Biology, Buffalo, New York, USA.
Ana RodriguezNew York University School of Medicine, Department of Microbiology, Division of Parasitology, New York, New York, USA ana.rodriguez@nyumc.org.
New York University · USRoswell Park Comprehensive Cancer Center · USUniversity of York · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Widespread resistance to most antimalaria drugs in use has prompted the search for novel candidate compounds with activity against Plasmodium asexual blood stages to be developed for treatment. In addition, the current malaria eradication programs require the development of drugs that are effective against all stages of the parasite life cycle. We have analyzed the antimalarial properties of xenomycins, a novel subclass of small molecule compounds initially isolated for anticancer activity and similarity to quinacrine in biological effects on mammalian cells. In vitro studies show potent activity of Xenomycins against Plasmodium falciparum. Oral administration of xenomycins in mouse models result in effective clearance of liver and blood asexual and sexual stages, as well as effective inhibition of transmission to mosquitoes. These characteristics position xenomycins as antimalarial candidates with potential activity in prevention, treatment and elimination of this disease.

Indexed as

AnimalsAnophelesAntimalarialsErythrocytesFemaleLife Cycle StagesMaleMiceNIH 3T3 CellsPlasmodiumAntimalarials

Identifiers

PMID25512429
PMCPMC4325811
OpenAlexW2085585307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.